NXL
Nexalin Technology, Inc.NASDAQHealthcare$0.35+2.33%ClosedMarket Cap: $7.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.79
P/S
24.57
EV/EBITDA
-0.82
DCF Value
$-0.24
FCF Yield
-66.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-310.3%
Operating Margin
-2781.7%
Net Margin
-2725.8%
ROE
-195.7%
ROA
-177.4%
ROIC
-223.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $171.9K | -334.3% | $-2.4M | $-2.4M | $-0.13 | — |
| FY 2025 | $301.6K | -543.4% | $-8.4M | $-8.2M | $-0.50 | — |
| Q3 2025 | $18.1K | -2405.7% | $-2.3M | $-2.3M | $-0.13 | — |
| Q2 2025 | $70.6K | 67.6% | $-1.6M | $-1.6M | $-0.10 | — |
| Q1 2025 | $41.0K | 66.9% | $-2.0M | $-2.0M | $-0.15 | — |
| Q4 2024 | $27.2K | 72.4% | $-2.9M | $-2.8M | $-0.29 | — |
| FY 2024 | $168.7K | 78.3% | $-7.8M | $-7.6M | $-0.83 | — |
| Q3 2024 | $36.0K | 64.8% | $-2.5M | $-2.4M | $-0.23 | — |
| Q2 2024 | $26.8K | 73.0% | $-1.3M | $-1.3M | $-0.17 | — |
| Q1 2024 | $78.7K | 88.4% | $-1.1M | $-1.0M | $-0.14 | — |
| Q4 2023 | $20.5K | 74.5% | $-1.6M | $-780.7K | $-0.10 | — |
| FY 2023 | $110.7K | 76.8% | $-5.7M | $-4.6M | $-0.63 | — |